ClinicalTrials.gg
CompletedNCT03203408Updated Oct 11, 2017

Efficacy of OSTENIL PLUS (Hyaluronic Acid) Versus SYNVISC-ONE in Patients With Tibiofemoral Osteoarthritis

An interventional study of OSTENIL PLUS and SYNVISC-ONE in Knee Osteoarthritis, sponsored by TRB Chemedica. Completed. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2017-10-11.

Sponsored by TRB Chemedica · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 6 years after the study started (first participant enrolled Jun 2011, registered Jun 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
290
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Study summary

The main objective of the study was to demonstrate the non-inferiority of the efficacy of a single intra-articular injection of OSTENIL PLUS compared to that of a single intra-articular injection of the reference product SYNVISC-ONE in the treatment of symptomatic tibiofemoral osteoarthritis. The primary endpoint was the change in mean score on the WOMAC pain scales from D0 to D180.

Read the detailed description

After a period of washout-out for NSAIDs, the patients received a single intra-articular injection of OSTENIL PLUS or of SYNVISC-ONE in the most painful knee. The study involved a preselection visit at D-7 and five further visits: at D0 (baseline, evaluation before intra-articular injection), at D2 ± 2 days (injection), at D30 ± 15 days, at D90 ± 15 days and C5 at D180 ± 15 days.

To enrol the patients as quickly as possible, 129 sites, i.e. general medical or rheumatology practices, were open. After verifying the inclusion and exclusion criteria, the evaluating investigators assigned a randomisation number based on the chronological order of inclusion of patients at their site. The patient was then sent to the injecting investigator so that he/she could give the injection of the product corresponding to the randomisation number.

02

Conditions studied

  • Knee Osteoarthritis
03

In context

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

This study's enrollment of 290 is above the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.

Browse Osteoarthritis, Knee studies →

Lead sponsor

TRB Chemedica is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 40-85 years;
  • Primary knee osteoarthritis complying with the American College or Rheumatology criteria;
  • Radiographically defined osteoarthritis: joint space narrowing and osteophyte in X-ray taken less than one year previously and modified Kellgren-Lawrence grade Ib-III;
  • Symptoms on one side only, with a mean WOMAC A of ≥40 mm. If knee osteoarthritis is bilateral, a difference for that score between the contralateral knee and the selected knee should be of at least 20 mm;
  • Pain present on at least 15 days in the month before inclusion;
  • Failure or intolerance of analgesics and NSAIDs;
  • With health insurance;
  • Understanding and following the study instructions;
  • Signed the .

Exclusion criteria

Exclusion Criteria:

  • Knee osteoarthritis that is not symptomatic or insufficiently symptomatic;
  • Bilateral symptomatic knee osteoarthritis of the same severity on both sides;
  • Post-traumatic secondary knee osteoarthritis;
  • Knee osteoarthritis of radiographic grade I, Ia or IV;
  • Exclusively patellofemoral osteoarthritis where the symptoms are principally of patellofemoral origin (Patellar syndrome);
  • Symptomatic homolateral coxarthrosis;
  • Varus or valgus deformation of the selected knee (deformation axis ≥15° in X-ray);
  • Inflammatory rheumatism (rheumatoid arthritis, psoriatic rheumatism, articular chondrocalcinosis, gout, Paget's disease, ankylosing spondylitis, lupus, etc.);
  • History of injury to the selected knee during the 6 months before inclusion;
  • Venous or lymphatic stenosis of the lower limb;
  • Femoral or sciatic nerve root pain of the lower limb to be tested;
  • Tendinopathy (e.g. hip periarthritis);
  • Treatment with intra-articular hyaluronic acid in the selected knee during the 6 months before inclusion;
  • Intra-articular injection of in the selected knee during the 2 months before inclusion;
  • Treatment with symptomatic slow-acting drugs for osteoarthritis and/or dietary supplements for osteoarthritis (chondroitin sulphate, diacerein, avocado and soybean unsaponifiables, oxaceprol, copper granions, glucosamine) which had been started less than 3 months previously or whose dose had been changed during the last 3 months before inclusion;
  • Total knee replacement of the selected knee;
  • Surgery of the other knee or of the hip or any other surgery scheduled during the period of the study;
  • History of any surgical intervention, arthroscopy, osteotomy, etc. in the year before inclusion;
  • Obesity: ≥30 kg/m2;
  • History of disease;
  • Severe condition likely to interfere with the evaluation, such as neoplasia, malignant blood disease, kidney disease, liver disease or severe infection;
  • Very marked hydrarthrosis (requiring puncture) at the time of inclusion;
  • Wound or skin condition of the selected knee;
  • Anticoagulant treatment with heparin or warfarin ( antiaggregants such as ASPIRIN ≤325 mg/d, ticlopidine or clopidogrel were allowed);
  • Known to hyaluronic acid and/or to avian proteins and/or paracetamol;
  • Known hypersensitivity to mannitol;
  • Participation in a clinical research study within the previous 3 months;
  • Pregnancy, breast-feeding.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
290 participants (actual)

Study arms

  • Experimental
    OSTENIL PLUS

    A single intra-articular injection of sodium hyaluronate 40 mg/2.0 ml at Day 2, i.e. 2 days post Baseline (Day 0 = Week 0)

    Device: OSTENIL PLUS

  • Active comparator
    SYNVISC-ONE

    A single intra-articular injection of hylan G-F 20 48 mg/6 ml at Day 2, i.e. 2 days post Baseline (Day 0 = Week 0)

    Device: SYNVISC-ONE

Interventions

  • DeviceOSTENIL PLUS

    Injection into the joint cavity of the most painful knee

  • DeviceSYNVISC-ONE

    Injection into the joint cavity of the most painful knee

06

What researchers measure

Primary outcomes

  1. Change in WOMAC A

    Change from baseline in the pain subscore (section A) of the WOMAC score

    Time frame: Day 0 to Day 180

Secondary outcomes

  1. Lequesne algofunctional index

    Index assessing the severity of osteoarthritis

    Time frame: Day 0 to Day 180

  2. WOMAC B

    Stiffness subscore (section B) of the WOMAC score

    Time frame: Day 0 to Day 180

  3. WOMAC C

    Function subscore (section C) of the WOMAC score

    Time frame: Day 0 to Day 180

  4. Patient's overall status score in relation to his/her knee osteoarthritis

    Visual analogue scale assessed by the patient

    Time frame: Day 0 to Day 180

  5. Assessment of overall treatment efficacy by the patient

    5-point scale (1 = very good; 2 = good; 3 = moderate; 4 = poor; 5 = very poor)

    Time frame: Day 30 to Day 180

  6. Assessment of overall treatment efficacy by the investigator

    5-point scale (1 = very good; 2 = good; 3 = moderate; 4 = poor; 5 = very poor)

    Time frame: Day 30 to Day 180

Other outcomes

  1. Incidence of all adverse events

    Recording of all adverse events and changes in concomitant treatments

    Time frame: Day 0 to Day 180

  2. Incidence of local adverse reactions

    Recording of adverse manifestations such as post-injection pain, inflammatory reaction, presence of hydrarthrosis, presence of acute pseudoseptic or septic arthritis

    Time frame: Day 30

  3. Assessment of local treatment tolerability by the patient

    5-point scale scale (1 = very good, 2 = good, 3= moderate, 4 = poor, 5 = very poor)

    Time frame: Day 30

  4. Assessment of local treatment tolerability by the investigator

    5-point scale scale (1 = very good, 2 = good, 3= moderate, 4 = poor, 5 = very poor)

    Time frame: Day 30

  5. Assessment of overall treatment tolerability by the investigator

    5-point scale (1 = very good; 2 = good; 3 = moderate; 4 = poor; 5 = very poor)

    Time frame: Day 30 to Day 180

  6. Assessment of overall treatment tolerability by the patient

    5-point scale (1 = very good; 2 = good; 3 = moderate; 4 = poor; 5 = very poor)

    Time frame: Day 30 to Day 180

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2011 to primary completion in Nov 2012, 17 months.

Of 139 industry-sponsored interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 34. This study's 17 months is close to that.

Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2017
First posted
Jun 29, 2017
StartActual
Jun 21, 2011
Primary completionActual
Nov 22, 2012
CompletionActual
Nov 22, 2012
Last update
Oct 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03203408
Lead sponsor
TRB Chemedica
Responsible party
Sponsor
First posted
Jun 29, 2017
Start date
Jun 21, 2011
Primary completion
Nov 22, 2012
Completion
Nov 22, 2012
Last update
Oct 11, 2017

Study contacts

Renée Liliane Dreiser, Dr
study chair · APHP Bichat-Claude Bernard, Paris, France
Bernard Avouac, Dr
study chair · APHP Henri Mondor, Creteil, France
Thomas Bardin, Prof.
principal investigator · APHP Lariboisière, Paris, France

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion